Journal of Pediatric Endocrinology and Metabolism · 2018 · 14 citations · 32 references
MedicineEndocrinologyPediatricsBone MetabolismPediatric EndocrinologyPediatric PharmacotherapyBone EndocrinologyBone GrowthChild GrowthGrowth AssessmentGrowth DisordersPubertyBone Age MaturationBone Tissue MaturationHormonal Regulation Of GrowthPediatric Bone EndocrinologyPubertal Bone DevelopmentPubertal Growth PredictionPubertal Skeletal GrowthPuberty Suppression
BACKGROUND: Children with central precocious puberty (CPP) are treated with gonadotropin-releasing hormone agonists (GnRHa) to suppress puberty. Optimizing treatment outcomes continues to be studied. The relationships between growth, rate of bone maturation (bone age/chronological age [ΔBA/ΔCA]), luteinizing hormone (LH), predicted adult stature (PAS), as well as variables influencing these outcomes, were studied in children treated with depot leuprolide (LA Depot) Methods: Subjects (64 girls, seven boys) with CPP received LA Depot every 3 months for up to 42 months. Multivariate regression analyses were conducted to examine the predictors affecting ΔBA/ΔCA, PAS and growth rate. RESULTS: Ninety percent of subjects (18 of 20) were suppressed (LH levels <4 IU/L) at 42 months. Over 42 months, the mean growth rate declined 2 cm/year, the mean BA/CA ratio decreased 0.21 and PAS increased 8.90 cm for girls (n=64). PAS improved to mid-parental height (MPH) in 46.2% of children by 30 months of treatment. Regression analysis showed that only the Body Mass Index Standardized Score (BMI SDS) was significantly associated (β+0.378 and +0.367, p≤0.05) with growth rate. For PAS, significant correlations were with MPH (β+0.808 and +0.791, p<0.001) and ΔBA/ΔCA (β+0.808 and +0.791, p<0.001). For ΔBA/ΔCA, a significant association was found only with BA at onset of treatment (β-0.098 and -0.103, p≤0.05). Peak-stimulated or basal LH showed no significant influence on growth rate, ΔBA/ΔCA or PAS. CONCLUSIONS: Growth rate and bone maturation rate normalized on treatment with LA Depot. LH levels were not significantly correlated with growth rate, ΔBA/ΔCA or PAS, suggesting that suppression was adequate and variations in gonadotropin levels were below the threshold affecting outcomes.
32
Normal ranges for immunochemiluminometric gonadotropin assays
E. Kirk Neely, Raymond L. Hintz, Darrell M. Wilson et al. · The Journal of Pediatrics · 1995 · 257 citations
Karen O. Klein, Kevin M. Barnes, Janet V. Jones et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 205 citations
Medicine, Endocrinology, Pediatrics +13
Jean‐Claude Carel, Marc Roger, S. Ispas et al. · The Journal of Clinical Endocrinology & Metabolism · 1999 · 174 citations
Medicine, Endocrinology, Pediatrics +11